Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01602822 · ClinicalTrials.gov registry record · Phase 4
Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV
A Phase 4 study, sponsored by Kenneth H. Mayer, MD.
- Terminated
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT01602822 is a Phase 4 study that was terminated before completion, run by Kenneth H. Mayer, MD. The registered enrollment target is 11 participants.
The verdict
NCT01602822, a Phase 4 study, was terminated before completion, sponsored by Kenneth H. Mayer, MD.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study will evaluate how safe and tolerable a combination of taking three-drugs will be for the purpose of preventing HIV transmission after a high-risk sexual contact exposure in HIV uninfected adults.
Interventions
- DRUG Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2012-02 |
| Est. Completion | 2012-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01602822
The ClinicalTrials.gov registry entry for NCT01602822 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kenneth H. Mayer, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir is the first listed.
NCT01602822 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01602822 about?
NCT01602822 is a clinical study titled "Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV". This study will evaluate how safe and tolerable a combination of taking three-drugs will be for the purpose of preventing HIV transmission after a high-risk sexual contact exposure in HIV uninfected adults.
What is the current status of trial NCT01602822?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2012-02. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01602822?
The interventions under investigation include: Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir (DRUG).
Who is sponsoring clinical trial NCT01602822?
This trial is sponsored by Kenneth H. Mayer, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.